A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

被引：379
|
作者：
Cobleigh, MA
Langmuir, VK
Sledge, GW
Miller, KD
Haney, L
Novotny, WF
Reimann, JD
Vassel, A
机构：
[1] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
[2] Genentech Inc, San Francisco, CA USA
[3] Indiana Univ, Indianapolis, IN 46204 USA
来源：
SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 05期
关键词：
D O I：
10.1053/j.seminoncol.2003.08.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：117 / 124
页数：8
相关论文
共 50 条
  • [31] Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
    Sylvie Négrier
    David Pérol
    Rastislav Bahleda
    Antoine Hollebecque
    Etienne Chatelut
    Helen Boyle
    Philippe Cassier
    Séverine Metzger
    Ellen Blanc
    Jean-Charles Soria
    Bernard Escudier
    BMC Cancer, 17
  • [32] Phase I trial of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
    Possinger, K
    Schippinger, W
    Kiewe, P
    Lange, W
    Preiss, J
    Niederle, N
    Brossart, P
    Papke, J
    Freier, W
    de Velde, HV
    Schmid, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 66S - 66S
  • [33] Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
    Negrier, Sylvie
    Perol, David
    Bahleda, Rastislav
    Hollebecque, Antoine
    Chatelut, Etienne
    Boyle, Helen
    Cassier, Philippe
    Metzger, Sevrine
    Blanc, Ellen
    Soria, Jean-Charles
    Escudier, Bernard
    BMC CANCER, 2017, 17
  • [34] Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer.
    Smit, WM
    Sufliarsky, J
    Spanik, S
    Wagnerová, M
    Kaye, S
    Oza, AM
    Gore, M
    Williams, K
    Johri, A
    Huinink, WWT
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 468S - 468S
  • [35] Phase I Dose-escalation Study of (SBRT) for Localizes Prostate Cancer
    Ghaly, M.
    Marrero, M.
    Vijeh, L.
    Montchal, E.
    Lee, L.
    Potters, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S391 - S391
  • [36] A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines
    Schmid, P.
    Kuehnhardt, D.
    Kiewe, P.
    Lehenbauer-Dehm, S.
    Schippinger, W.
    Greil, R.
    Lange, W.
    Preiss, J.
    Niederle, N.
    Brossart, P.
    Freier, W.
    Kuemmel, S.
    de Velde, H. Van
    Regierer, A.
    Possinger, K.
    ANNALS OF ONCOLOGY, 2008, 19 (05) : 871 - 876
  • [37] Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors
    Aspeslagh, Sandrine
    Awada, Ahmad
    Matos-Pita, Arturo S.
    Aftimos, Philippe
    Bahleda, Ratislav
    Varga, Andrea
    Soria, Jean-Charles
    ANTI-CANCER DRUGS, 2016, 27 (10) : 1021 - 1027
  • [38] A phase I/II dose-escalation/efficacy study, of single fraction stereotactic body radiotherapy (SF-SBRT) for metastatic cancer
    Urbanic, J. J.
    McMullen, K. P.
    Stieber, V. W.
    Hinson, W. H.
    Kearns, W. T.
    Hampton, C. J.
    Lovato, J. F.
    Livengood, K.
    Rosdahl, R.
    Blackstock, A. W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S140 - S140
  • [39] Bevacizumab in patients with previously treated metastatic colorectal cancer: preliminary results of a phase II study (bevacolor)
    Borg, C.
    Delord, J. P.
    Husseini, F.
    Lenoir, V. Trillet
    Faroux, R.
    Francois, E.
    Ychou, M.
    Bergougnoux, L.
    Bennouna, J.
    Douillard, J. Y.
    EJC SUPPLEMENTS, 2007, 5 (04): : 257 - 257
  • [40] A phase I dose-escalation trial of alpha-tocopheryloxyacetic acid and concurrent trastuzumab in patients with treatment refractory HER2+metastatic breast cancer.
    Gwin, William R.
    Childs, Jennifer
    Higgins, Doreen
    Burton, Kellie Ann
    Kuano, Kristin
    Corulli, Lauren
    Dai, James
    Akporiaye, Emmanuel T.
    Disis, Mary L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345